![](https://webarchive.library.unt.edu/web/20090509164430im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/web/20090509164430im_/http://www.cancer.gov/images/spacer.gif)
buspirone hydrochloride The hydrochloride salt of an anxiolytic agent chemically and pharmacologically unrelated to benzodiazepines, barbiturates, or other sedative/hypnotic drugs. Although its exact mechanism of action is unknown, buspirone may exert its anti-anxiety effects via serotonin (5-HT1A) and dopamine receptors (D2) and may indirectly affect other neurotransmitter systems. Unlike typical benzodiazepine anxiolytics, this agent does not exert anticonvulsant or muscle relaxant effects and lacks prominent sedative effects. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/web/20090509164430im_/http://www.cancer.gov/images/spacer.gif)
US brand name: | ![](https://webarchive.library.unt.edu/web/20090509164430im_/http://www.cancer.gov/images/spacer.gif) | Buspar | | ![](https://webarchive.library.unt.edu/web/20090509164430im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20090509164430im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20090509164430im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/web/20090509164430im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20090509164430im_/http://www.cancer.gov/images/spacer.gif) |